本文關鍵詞： 白血病干細胞 CD CD 急性白血病 療效 預后　出處：《吉林大學學報(醫(yī)學版)》2017年04期 　論文類型：期刊論文

【摘要】：目的:觀察白血病干細胞(LSC)表面CD96和CD71表達對急性白血病患兒療效及預后的影響,闡明白血病患兒LSC的分子生物學特征與其療效和預后的關聯(lián)性。方法:選擇80例急性白血病患兒作為研究對象,其中急性淋巴細胞白血病(ALL)39例,急性髓系白血病(AML)41例。應用流式細胞術對其LSC表面CD96和CD71表達情況進行檢測,對患者的首次化療療效、5年生存率、化療后感染、化療后復發(fā)和髓外浸潤發(fā)生率進行觀察和比較。結果:38例(47.5%)患兒LSC表面CD96陽性表達,45例(56.3%)患兒LSC表面CD71陽性表達,2種抗原陽性表達率比較差異無統(tǒng)計學意義(χ~2=1.227,P=0.268);AML患兒LSC表面CD96和CD71陽性表達率均明顯高于ALL患兒(χ~2=22.225,χ~2=34.028,均P0.01)。LSC表面CD96陰性表達患兒首次化療后的臨床有效率和療效分布均優(yōu)于LSC表面CD96陽性表達患兒,LSC表面CD71陰性表達的患兒首次化療后的臨床有效率和療效分布優(yōu)于LSC表面CD71陽性表達患兒(χ~2=11.323,χ~2=16.589,P0.05;U=2.939,U=2.291,P0.05)。LSC表面CD96陰性表達患兒的5年生存率明顯高于LSC表面CD96陽性表達患兒(χ~2=5.051,P0.05),化療后感染、化療后復發(fā)和髓外浸潤發(fā)生率明顯低于LSC表面CD96陽性表達患兒(χ~2=8.316,χ~2=13.288,χ~2=5.389,均P0.05);LSC表面CD71陰性表達患兒化療后感染發(fā)生率和化療后復發(fā)率明顯低于LSC表面CD71陽性表達的患兒(χ~2=6.622,χ~2=10.787,均P0.05)。結論:急性白血病患兒LSC表面的CD96和CD71表達水平與疾病亞型、首次化療療效具有一定的關聯(lián)性,可作為輔助診斷和評價療效的標志物;CD96的表達水平與患者的預后具有關聯(lián)性,可作為預測患兒預后的指標。
[Abstract]:Objective: to observe the effect of CD96 and CD71 expression on acute leukemia in children with acute leukemia. Objective: to elucidate the relationship between molecular biological characteristics of LSC and its curative effect and prognosis in children with leukemia. Methods: 80 children with acute leukemia were selected as study subjects. Among them, 39 cases of acute lymphoblastic leukemia (ALL) and 41 cases of acute myeloid leukemia (AMLL) were detected by flow cytometry. The expression of CD96 and CD71 on the surface of LSC was detected by flow cytometry. For the first time chemotherapy, 5-year survival rate, infection after chemotherapy. The incidence of recurrence and extramedullary infiltration after chemotherapy was observed and compared. Results the positive expression of CD96 was found on the surface of LSC in 38 cases of LSC. There was no significant difference in the positive expression rate of CD71 on the surface of LSC between 45 cases (56.3%) and 0.268% (蠂 ~ 2 + 1.227). The positive expression rates of CD96 and CD71 on the surface of LSC in children with AML were significantly higher than those in children with ALL (蠂 2: 22. 225, 蠂 2: 34. 028). The clinical effective rate and curative effect distribution of patients with negative expression of CD96 on the surface of P0.01U 路LSC were better than those of the patients with positive expression of CD96 on the surface of LSC after the first chemotherapy. The clinical effective rate and curative effect distribution of children with CD71 negative expression on LSC surface after first chemotherapy were better than those with CD71 positive expression on LSC surface (蠂 2 + 11.323). 蠂 2 + 16.589 (P 0.05); Uf2. 939, U2. 291. The 5-year survival rate of patients with negative expression of CD96 on the surface of P0.05N 路LSC was significantly higher than that of those with positive expression of CD96 on the surface of LSC (蠂 2 / 5.051 / P0.05). The incidence of infection, recurrence and extramedullary infiltration after chemotherapy was significantly lower than that in children with positive expression of CD96 on the surface of LSC (蠂 2 + 8.316, 蠂 2 + 13.288, 蠂 2 + 5.389). P0.05; The incidence of infection after chemotherapy and recurrence after chemotherapy in children with negative expression of CD71 on the surface of LSC were significantly lower than those with positive expression of CD71 on the surface of LSC (蠂 2 + 6.622). Conclusion: the expression of CD96 and CD71 on the surface of LSC in children with acute leukemia is correlated with the subtype of the disease and the curative effect of the first chemotherapy. It can be used as a marker of auxiliary diagnosis and evaluation of curative effect. The expression of CD96 is correlated with the prognosis of the patients and can be used as a predictor of prognosis.
【作者單位】： 吉林大學第一醫(yī)院小兒腫瘤科;吉林大學第一醫(yī)院急診內(nèi)科;
【基金】：吉林省科技廳科技發(fā)展計劃項目資助課題(20130486)
【分類號】：R733.71
【正文快照】： 白血病是一種源于造血干細胞的惡性克隆性疾病,急性白血病是多發(fā)于兒童的惡性血液疾病,近年來,隨著聯(lián)合化療、造血干細胞移植等針對白血病治療方案的不斷改進,兒童急性白血病的治療效果得到了大幅度提升[1-3]。目前,急性淋巴細胞性白血病(acute lymphocytic leukemia,ALL)和急

【參考文獻】

相關期刊論文 前10條

1 羅穎婉;佟紅艷;;骨髓增生異常綜合征相關病因研究進展[J];中國實用內(nèi)科雜志;2017年03期

2 宋曉潔;馮偉平;韓雪嬌;張魯壯;崔喜財;;CD47在急性白血病干細胞中的表達及其對臨床療效及預后的影響[J];現(xiàn)代生物醫(yī)學進展;2016年29期

3 劉春燕;邵宗鴻;;再生障礙性貧血發(fā)病機制研究進展[J];中國實用內(nèi)科雜志;2016年05期

4 黃暉婷;彭琪;夏平方;魏姍姍;李倩;佘妙容;;靶向骨髓微環(huán)境治療急性白血病的研究進展[J];國際輸血及血液學雜志;2016年02期

5 鄒東方;文飛球;于潔;;急性白血病化療對兒童認知功能影響評估的研究進展[J];中國實用兒科雜志;2015年10期

6 王毅捷;孫和順;馬亞震;;CD96及P選擇素在急性白血病患者外周血中的表達及臨床意義[J];血栓與止血學;2015年01期

7 魏園玉;張曉樞;張帆;李f灘，

本文編號：1467601